DRUG

Sitagliptin

6 hypotheses across 4 therapeutic domains

CROSS-DOMAIN PATTERN

Same drug, multiple disease domains

Sitagliptin appears in hypotheses across 4 disease domains: ALS, Depression, Inflammatory bowel disease, Rheumatoid arthritis. Shared mediators that recur across at least two of those domains: DPP4.

Aggregated from the catalog. Biological interpretation of any multi-indication mechanism would require independent validation — this is a structural observation only.

ALL HYPOTHESES

Repurposing candidates for Sitagliptin

ALS 1

Mediator Outcome Score Tier Lit. status Trial
DPP4 microglial dysregulation 0.277 High novel signal none

Depression 1

Mediator Outcome Score Tier Lit. status Trial
BDNF schizophrenia 0.208 Mid partial evidence none

Inflammatory bowel disease 3

Mediator Outcome Score Tier Lit. status Trial
DPP-4 disease activity 0.271 High partial evidence completed
DPP-4 biological treatment response 0.230 Mid novel signal none
DPP-4 treatment escalation 0.230 Mid partial evidence completed

Rheumatoid arthritis 1

Mediator Outcome Score Tier Lit. status Trial
DPP4 autoimmune diseases 0.277 High reproduces known completed

Clinical trials

200 registered trials for Sitagliptin

Source: ClinicalTrials.gov

← All drugs